The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Increased sugar uptake promotes oncogenesis via EPAC/RAP1 and O-GlcNAc pathways
Open accessAbstract
There is a considerable resurgence of interest in the role of aerobic glycolysis in cancer; however, increased glycolysis is frequently viewed as a consequence of oncogenic events that drive malignant cell growth and survival. Here we provide evidence that increased glycolytic activation itself can be an oncogenic event in a physiologically relevant 3D culture model. Overexpression of glucose transporter type 3 (GLUT3) in nonmalignant human breast cells activated known oncogenic signaling pathways, including EGFR, β1 integrin, MEK, and AKT, leading to loss of tissue polarity and increased growth. Conversely, reduction of glucose uptake in malignant cells promoted the formation of organized and growth-arrested structures with basal polarity, and suppressed oncogenic pathways. Unexpectedly and importantly, we found that unlike reported literature, in 3D the differences between "normal" and malignant phenotypes could not be explained by HIF-1α/2α, AMPK, or mTOR pathways. Loss of epithelial integrity involved activation of RAP1 via exchange protein directly activated by cAMP (EPAC), involving also O-linked N-acetylglucosamine modification downstream of the hexosamine biosynthetic pathway. The former, in turn, was mediated by pyruvate kinase M2 (PKM2) interaction with soluble adenylyl cyclase. Our findings show that increased glucose uptake activates known oncogenic pathways to induce malignant phenotype, and provide possible targets for diagnosis and therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425 · cited 4×
“Curiously, Warburg’s original hypothesis that aerobic glycolysis itself could be the “origin of cancer cells” (2) had not been proven directly.”
InfluentialOtto Warburg's contributions to current concepts of cancer metabolism
Koppenol, W. H., Bounds, P. L., & Dang, C. V. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3038 · Cited by 3,427
The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth
Christofk, H. R., Vander Heiden, M. G., Harris, M. H., Ramanathan, A., Gerszten, R. E., Wei, R., Fleming, M. D., Schreiber, S. L., & Cantley, L. C. (2008) · Nature · doi:10.1038/nature06734 · Cited by 2,820 · cited 1×
“The literature indicates that the protein level of PKM2 is frequently increased in cancer cells, whereas that of PKM1 is reduced (35, 61).”
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366
Tumor cell metabolism: cancer's Achilles' heel
Kroemer, G., & Pouyssegur, J. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.05.005 · Cited by 2,337
TIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis
Bensaad, K., Tsuruta, A., Selak, M. A., Vidal, M. N. C., Nakano, K., Bartrons, R., Gottlieb, E., & Vousden, K. H. (2006) · Cell · doi:10.1016/j.cell.2006.05.036 · Cited by 2,019 · cited 1×
“and thus confers resistance to cell death (10, 11).”
The LKB1-AMPK pathway: metabolism and growth control in tumour suppression
Shackelford, D. B., & Shaw, R. J. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2676 · Cited by 1,943 · cited 1×
“29), were slightly higher in T4-2 cells compared with S1 or 2DG-treated T4-2 cells (Figure 4A), which indicates that the mTOR pathway could be influenced only modestly by inhibition of glucose metabolism in 3D. Never-theless, mTOR inhibitors, such as rapamycin and PP242, did not induce phenotypic…”
Weaver, V. M., Petersen, O. W., Wang, F., Larabell, C. A., Briand, P., Damsky, C., & Bissell, M. J. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.137.1.231 · Cited by 1,483 · cited 1×
“Using a physiologically relevant 3D assay and a breast cancer progression series (20, 28) as well as other breast cancer cell lines, we showed here that overexpression of a glucose transporter in a nonmalignant human breast epithelial cell disrupted polarity and formation of organized tissue-like acini in 3D cultures…”
Self-citationThe Control of the Metabolic Switch in Cancers by Oncogenes and Tumor Suppressor Genes
Levine, A. J., & Puzio-Kuter, A. M. (2010) · Science · doi:10.1126/science.1193494 · Cited by 1,243 · cited 1×
“Numerous intermediary glucose metabolites are used for diverse biosynthetic processes (7), and NADPH, a reducing equivalent generated by glucose metabolism, sequesters ROS”
Cited by
Targeting integrin pathways: mechanisms and advances in therapy
Pang, X., He, X., Qiu, Z., Zhang, H., Xie, R., Liu, Z., Gu, Y., Zhao, N., Xiang, Q., & Cui, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01259-6 · Cited by 1,275
Three-dimensional culture systems in cancer research: Focus on tumor spheroid model
Nath, S., & Devi, G. R. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.03.013 · Cited by 919
San-Millán, I., & Brooks, G. A. (2016) · Carcinogenesis · doi:10.1093/carcin/bgw127 · Cited by 610
Analysis and Interpretation of Microplate-Based Oxygen Consumption and pH Data
Divakaruni, A. S., Paradyse, A., Ferrick, D. A., Murphy, A. N., & Jastroch, M. (2014) · Methods in Enzymology · doi:10.1016/b978-0-12-801415-8.00016-3 · Cited by 518
PKM2, function and expression and regulation
Zhang, Z., Deng, X., Liu, Y., Liu, Y., Sun, L., & Chen, F. (2019) · Cell & Bioscience · doi:10.1186/s13578-019-0317-8 · Cited by 498
Broad targeting of angiogenesis for cancer prevention and therapy
Wang, Z., Dabrosin, C., Yin, X., Fuster, M. M., Arreola, A., Rathmell, W. K., Generali, D., Nagaraju, G. P., El-Rayes, B., Ribatti, D., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.01.001 · Cited by 464
Aerobic glycolysis tunes YAP/TAZ transcriptional activity
Enzo, E., Santinon, G., Pocaterra, A., Aragona, M., Bresolin, S., Forcato, M., Grifoni, D., Pession, A., Zanconato, F., Guzzo, G., et al. (2015) · The EMBO Journal · doi:10.15252/embj.201490379 · Cited by 414
Four Key Steps Control Glycolytic Flux in Mammalian Cells
Tanner, L. B., Goglia, A. G., Wei, M. H., Sehgal, T., Parsons, L. R., Park, J. O., White, E., Toettcher, J. E., & Rabinowitz, J. D. (2018) · Cell Systems · doi:10.1016/j.cels.2018.06.003 · Cited by 378
Chen, W.-H., Luo, G.-F., Lei, Q., Hong, S., Qiu, W.-X., Liu, L.-H., Cheng, S.-X., & Zhang, X.-Z. (2017) · ACS Nano · doi:10.1021/acsnano.6b06658 · Cited by 367
Biology, vulnerabilities and clinical applications of circulating tumour cells
Ring, A., Nguyen-Sträuli, B. D., Wicki, A., & Aceto, N. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00536-4 · Cited by 327
O-GlcNAcylation in Cancer Biology: Linking Metabolism and Signaling
Ferrer, C. M., Sodi, V. L., & Reginato, M. J. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.05.028 · Cited by 267
Interplay between epigenetics and metabolism in oncogenesis: mechanisms and therapeutic approaches
Wong, C. C., Qian, Y., & Yu, J. (2017) · Oncogene · doi:10.1038/onc.2016.485 · Cited by 262
Better together: circulating tumor cell clustering in metastatic cancer
Schuster, E., Taftaf, R., Reduzzi, C., Albert, M. K., Romero-Calvo, I., & Liu, H. (2021) · Trends in Cancer · doi:10.1016/j.trecan.2021.07.001 · Cited by 260
Metabolic reprogramming in triple-negative breast cancer
Wang, Z., Jiang, Q., & Dong, C. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2019.0210 · Cited by 248
“In contrast, decreasing glucose uptake in breast cancer cells suppresses these oncogenic pathways and promotes the formation of organized structures 20 .”
BackgroundHuang, B.-W., & Gao, J.-Q. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.12.005 · Cited by 174
Metadata
- Authors
- Onodera, Y., Nam, J.-M., & Bissell, M. J.
- Venue
- Journal of Clinical Investigation
- Published
- 2013-12-09
- Volume
- 124
- Issue
- 1
- Pages
- 367-384
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2145181376
- Cited by
- 209
- References
- 15
- FWCI
- 6.00
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.